PDCD1 and Hodgkins lymphoma: However, the loss or reduced expression of MHC class I and II molecules on HRS cells14 would be expected to limit neoantigen presentation and subsequent effector T-cell function, suggesting that additional and/or alternate mechanisms may contribute to the response to PD-1 blockade therapy in HL.